Introduction On May 27, 2025, in Zeria Pharmaceutical Co. Ltd. v. Deputy Controller of Patents and Designs1, the Delhi High Court upheld the refusal of divisional patent, affirming that minor structural modifications of known pharmaceutical compounds—especially intermediates—must still demonstrate enhanced therapeutic efficacy to be patentable under Section 3(d) of the Indian Patents Act, 1970. The […]
